hATG

DRUG2 trials

Sponsors

European Society for Blood and Marrow Transplantation, Novartis Pharmaceuticals

Conditions

Aplastic AnemiaSevere Aplastic Anemia

Phase 2

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

CompletedNCT03025698

Novartis PharmaceuticalsAplastic Anemia

Start: 2017-09-30End: 2025-01-27Updated: 2025-03-04

Phase 3

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

CompletedNCT02099747

European Society for Blood and Marrow TransplantationSevere Aplastic Anemia

Start: 2015-07-31End: 2020-12-31Updated: 2020-12-22

Related Papers

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia

Blood2025-11-03

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial

Blood Advances2025-05-023 citations

Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial

Blood2024-11-052 citations

Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia.

2023-12-131 citations

Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial

Blood2022-11-153 citations

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

New England Journal of Medicine2022-01-05262 citations

Somatic mutations in aplastic anemia: Significance for classification, therapy, and outcome

HemaSphere2019-06-012 citations